Results 51 to 60 of about 68,845 (338)

Progesterone, Progestins, and the Heart

Reviews in Cardiovascular Medicine, 2010
All combination hormone replacement regimens contain estrogen and a progestational agent. The Women's Health Initiative trial demonstrated that taking the combination of conjugated estrogen and medroxyprogesterone resulted in a higher risk of myocardial infarction and stroke in the study population.
Gerald M. Pohost, Paula Bernstein
openaire   +3 more sources

Effects of Etisterone and Contrasmine pills on clinical and biochemical findings of hyperandrogenism and metabolic parameters of patients with polycystic ovary syndrome: A randomized clinical trial [PDF]

Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2020
Introduction: Nowadays, selection of a contraceptive with most anti-androgenic effects is an important challenge in treatment of patients with polycystic ovary syndrome (PCOS).
Mina Amiri, Razieh Bidhendi-Yarandi, Fatemeh Nahidi, Fahimeh Ramezani Tehrani   +3 more
doaj   +1 more source

Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 Oxidoreductase deficiency [PDF]

, 2010
Context: P450 oxidoreductase (POR) is a crucial electron donor to all microsomal P450 cytochrome (CYP) enzymes including 17α-hydroxylase (CYP17A1), 21-hydroxylase (CYP21A2) and P450 aromatase.
Adachi, Antley, Arlt, Auchus, Belgorosky, Birgit Köhler, Bulun, Byskov, Cedric H. L. Shackleton, Dharia, Dhir, Dominique Maiter, Ewa M. Malunowicz, Falhammar, Felicity Collins, Flück, Fujieda, Fukami, Fukami, Fukami, Grondahl, Grøndahl, Hague, Huang, Huang, Idkowiak, Jan Idkowiak, Jin, Krone, Latronico, Luitgard Margarete Graul-Neumann, Mallin, Mann, Maria Szarras-Czapnik, Martin Silink, Mehul Dattani, Michiel N. Kerstens, Mullis, New, Nguyen, Nicole Reisch, Nils Krone, Otto, Ribes, Rosa, Roux, Rozman, Sahakitrungruang, Schmidt, Shackleton, Shima, Stephen O'Riordan, Suzuki, Tanae, ten Kate-Booij, Tomalik-Scharte, Wang, Wang, Wiebke Arlt, Wilson   +59 more
core   +2 more sources

Molecular Classification in Patients With Endometrial Cancer After Fertility-Preserving Treatment: Application of ProMisE Classifier and Combination of Prognostic Evidence

Frontiers in Oncology, 2022
The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) is a molecular classification system that identifies endometrial cancer (EC) into four prognostically distinct subtypes: POLE-mutated, mismatch repair deficiency (MMR-D), p53 wild ...
Xuting Ran, Xuting Ran, Tingwenyi Hu, Tingwenyi Hu, Zhengyu Li, Zhengyu Li   +5 more
doaj   +1 more source

Hormonal contraceptive methods and risk of HIV acquisition in women : a systematic review of epidemiological evidence [PDF]

, 2014
Peer reviewedPublisher ...
Curtis, Kathryn M., Hannaford, Philip, Phillips, Sharon J., Polis, Chelsea B., Raymond, Elizabeth, Steyn, Petrus S., Turner, Abigail Norris, Westreich, Daniel J.   +7 more
core   +2 more sources

Treatment of symptoms of the menopause: an endocrine society clinical practice guideline [PDF]

, 2015
Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and
Davis, Susan R., Gompel, Anne, Lumsden, Mary Ann, Murad, M. Hassan, Pinkerton, JoAnn V., Santen, Richard J., Stuenkel, Cynthia A.   +6 more
core   +1 more source

Integration of Bioengineered Tools in Assisted Reproductive Technologies

Advanced Healthcare Materials, EarlyView.
A conceptual illustration depicting the collaboration between a medical professional (right) and a scientist (left). Their connection highlights the integration of scientific research and clinical practice. This representation underscores the role of emerging technologies in bridging fundamental research with applied reproductive healthcare.
Aslı Ak, Edith Coonen, Ron van Golde, Erik Vrij   +3 more
wiley   +1 more source

Phosphorylation of IDH1 Facilitates Progestin Resistance in Endometrial Cancer

Advanced Science
The progestin regimen is one of the main therapeutic strategies for women with endometrial cancer who undergo conservative management. Although many patients respond well to initial therapy, progestin‐refractory disease inevitably emerges, and the ...
Jingjie Li, Zuoshu Qin, Yunqi Li, Baozhu Huang, Qimeng Xiao, Peiqin Chen, Yifan Luo, Wenxin Zheng, Tao Zhang, Zhenbo Zhang   +9 more
doaj   +1 more source

Neurohypophysial and paracrine vasopressinergic signaling regulates aquaporin trafficking to hydrate marine teleost oocytes

Frontiers in Endocrinology, 2023
The dual aquaporin (Aqp1ab1/Aqp1ab2)-mediated hydration of marine teleost eggs, which occurs during oocyte meiosis resumption (maturation), is considered a key adaptation underpinning their evolutionary success in the oceans.
Alba Ferré, François Chauvigné, Magdalena Gozdowska, Ewa Kulczykowska, Roderick Nigel Finn, Roderick Nigel Finn, Joan Cerdà   +6 more
doaj   +1 more source

Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer

Journal of Gynecologic Oncology, 2016
Objective To report our 15-year institutional experience of fertility-sparing treatment in young patients with early endometrial cancer (EC) treated by combined hysteroscopic resection and progestin therapy.
F. Falcone, G. Laurelli, S. Losito, M. Di Napoli, V. Granata, S. Greggi   +5 more
semanticscholar   +1 more source